Survodutide
Medium EvidenceA dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026.
What It Is
Survodutide (BI 456906) is a dual agonist targeting both GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. The glucagon receptor component increases energy expenditure and promotes hepatic fat oxidation, while GLP-1 reduces appetite — a complementary dual mechanism. In April 2026, Boehringer announced positive Phase 3 SYNCHRONIZE-1 topline results: adults with obesity or overweight (without T2D) achieved 16.6% mean weight loss at 76 weeks versus 3.2% with placebo, and 85.1% reached ≥5% body weight reduction. Statistically significant reductions in waist circumference — a marker of visceral fat and cardiometabolic risk — were also reported. Full SYNCHRONIZE-1 and SYNCHRONIZE-MASLD data will be presented at the ADA 2026 Scientific Sessions in New Orleans. Results from the Phase 3 SYNCHRONIZE-2 (obesity with T2D) and SYNCHRONIZE-CVOT (cardiovascular outcomes) trials are expected later in 2026. The LIVERAGE Phase 3 program in MASH is also enrolling. Survodutide's liver-targeted glucagon activity distinguishes it from pure GLP-1 agonists and positions it as a leading candidate in the MASH therapeutic space alongside pemvidutide. In the emerging competitive landscape, survodutide's 16.6% weight loss at 76 weeks in SYNCHRONIZE-1 positions it below tirzepatide and retatrutide for weight loss magnitude but its dual mechanism (GLP-1 + glucagon rather than GLP-1 + GIP) offers a differentiated approach — particularly for liver fat reduction in MASH, where glucagon-mediated hepatic fat oxidation is the key therapeutic advantage. The Phase 3 SYNCHRONIZE program includes both obesity (SYNCHRONIZE-1) and MASH-specific (SYNCHRONIZE-NASH) arms, making survodutide one of the only peptides pursuing simultaneous registration for both indications. In Phase 2 MASH data, survodutide demonstrated histological improvement in liver fibrosis and MASH resolution at rates significantly exceeding placebo, with substantial reductions in hepatic fat content. A 2026 Priority Review NDA filing with the FDA positions survodutide for potential approval as the first peptide therapy specifically indicated for MASH.
Proposed Mechanisms
- GLP-1 receptor agonism suppresses appetite and reduces caloric intake
- Glucagon receptor activation increases hepatic energy expenditure and lipid oxidation
- Dual mechanism promotes weight loss through both reduced intake and increased expenditure
- Improves hepatic lipid metabolism, reducing liver fat accumulation
- Enhances insulin sensitivity through combined metabolic pathway modulation
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (Phase 2) | Adults with obesity, no T2D (n=387) | Up to 18.7% weight loss at 46 weeks with 4.8mg dose | Source |
| Human (Phase 2, NEJM) | Adults with MASH and fibrosis (n=293) | 62% MASH improvement at 4.8mg vs 14% placebo; ≥30% liver fat reduction in 67%; fibrosis improvement in 34–36% | Source |
| Human (Phase 3, SYNCHRONIZE-1) | Adults with obesity/overweight without T2D (n=725, 14 countries) | 16.6% mean weight loss with meaningful metabolic improvement; topline results April 2026 | Source |
| Human (Phase 3, SYNCHRONIZE-1 topline) | Adults with obesity/overweight without T2D (n=725, 14 countries), 76 weeks | 16.6% mean weight loss vs 3.2% placebo; 85.1% achieved ≥5% loss; significant waist circumference reduction | Source |
Commonly Discussed Benefits
Safety & Cautions
- NDA filed February 2026 under Priority Review; FDA decision expected Q3 2026 at earliest
- FDA Breakthrough Therapy designation granted for MASH (non-cirrhotic, fibrosis stages 2–3)
- Gastrointestinal side effects reported in trials (nausea, vomiting)
- Long-term cardiovascular safety data not yet available; SYNCHRONIZE-CVOT planned
- Not yet FDA-approved; available only through clinical trial participation until approval
Comparisons
See how Survodutide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Survodutide Phase 2 MASH trial — NEJM 2024 PubMed
- [2] Survodutide Phase 2 obesity trial — Lancet 2024 PubMed
- [3] SYNCHRONIZE-2 baseline characteristics — Diabetes Obes Metab 2026 PubMed
- [4] SYNCHRONIZE-1 baseline characteristics — PubMed 2026 PubMed
- [5] Boehringer Ingelheim — SYNCHRONIZE-1 Phase 3 topline results, April 2026 PubMed
- [6] FDA Grants Survodutide Breakthrough Therapy Designation for MASH — Pharmacy Times 2026 PubMed
- [7] Boehringer Ingelheim — Phase III SYNCHRONIZE-1 topline results. April 28, 2026 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Retatrutide
High EvidenceAn investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.
Mazdutide
High EvidenceThe first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide.
Maridebart Cafraglutide (MariTide)
Medium EvidenceAmgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1.
MariTide
High EvidenceA bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes.
NA-931 (Bioglutide)
Medium EvidenceThe first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation.
UBT251
Medium EvidenceA GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space.